The Institute of Medicine (IOM) recently released a report assessing the global public health implications of falsified, substandard, and counterfeit pharmaceuticals to help begin an international conversation about the problem.
The report lays out a plan to improve public health, including a call for the World Health Organization to develop international guidelines for monitoring and regulating fake drugs, as well as for states to improve licensing requirements for drug wholesalers and distributors.
As a member of the Pharmaceutical Distribution Security Alliance (PDSA), a coalition of more than 25 pharmacies, distributors, logistic operators, manufacturers and associations committed to strengthening the nation’s pharmaceutical distribution supply chain, AstraZeneca supports a federal supply chain solution, including:
- Long overdue federal uniform standard on drug traceability to ensure greater patient safety
- Solutions that are cost-efficient and meet the needs of individual
The PDSA issued a statement responding to the IOM report, in part saying:
“The Pharmaceutical Distribution Security Alliance applauds the Institute of Medicine for recognizing that new legislation is needed to protect all Americans from the threat of counterfeit drugs. PDSA is particularly pleased that the IOM recognized that the supply chain can only be as strong as its weakest link and that a national solution is a necessary safeguard. As the IOM report noted, to prevent fake drugs from ending up in patients’ hands, Congress should pass legislation that creates a national system for drug distribution security.”
We applaud Congress’ interest and encourage action early this year.